Clinical Trials
4
Active:0
Completed:2
Trial Phases
3 Phases
Phase 2:1
Phase 4:2
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 4
2 (50.0%)Not Applicable
1 (25.0%)Phase 2
1 (25.0%)Fecal Microbiota Therapy for Recurrent Clostridium Difficile Infection
Phase 2
- Conditions
- Clostridium Difficile Infection
- Interventions
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2016-09-27
- Lead Sponsor
- Queen Elizabeth II Health Sciences Centre
- Target Recruit Count
- 50
- Registration Number
- NCT02686645
Brain Trauma Outcomes in Nova Scotia Study
Not Applicable
Completed
- Conditions
- Brain Injuries,TraumaticOutcome Assessment (Health Care)Craniocerebral TraumaEmergency Medical ServicesOrganizational Innovation
- First Posted Date
- 2010-10-21
- Last Posted Date
- 2010-10-21
- Lead Sponsor
- Queen Elizabeth II Health Sciences Centre
- Target Recruit Count
- 52
- Registration Number
- NCT01225692
Prevention of Instent Renarrowing With Aggressive Glucose Lowering With Pioglitazone in Diabetic Patients
Phase 4
Completed
- Conditions
- Coronary Artery DiseaseAngina PectorisType 2 Diabetes MellitusPercutaneous Coronary Intervention
- Interventions
- Drug: oral hypoglycemic agents
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2009-01-08
- Lead Sponsor
- Queen Elizabeth II Health Sciences Centre
- Target Recruit Count
- 50
- Registration Number
- NCT00819325
- Locations
- 🇨🇦
Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients
Phase 4
- Conditions
- Pertussis
- First Posted Date
- 2006-06-12
- Last Posted Date
- 2007-10-23
- Lead Sponsor
- Queen Elizabeth II Health Sciences Centre
- Target Recruit Count
- 10
- Registration Number
- NCT00336115
News
Gene Therapy for Fabry Disease Shows Promise with $3.7 Million Cost Savings in Early-Stage Trial
A small-scale gene therapy study for Fabry disease enabled three of five male patients to discontinue costly enzyme-replacement therapy, generating $3.7 million in savings against $4 million research costs.